RDIF announced the positive results of the KI favipiravir

The Russian direct investment Fund (RDIF) and a group of companies “Chemrar” announced the receipt of a positive first interim results of a multicenter randomized comparative open clinical study of the drug favipiravir, which takes place in patients hospitalized with COVID-19.

According to the data collected, 60% of patients (from 40 participants) receiving favipiravir had a negative test for the coronavirus after 5 days of therapy. This figure was 2 times higher than in the group of standard therapy. The data coincide with the results of the Chinese studies that also showed reduction in the duration of the disease from 11 days to 4-5 days.

The next important step is obtaining a registration certificate on possibility of application of favipiravir in the entire country, then the group of companies “Chemrar” in cooperation with the RDIF can start commercial supplies of the drug at the end of may.

To date have produced 250 courses of the drug, another 1,500 courses in stage production, said the CEO of RDIF Kirill Dmitriev. He said that together with GK “Khimrar” established technological lines for production of up to 600,000 courses a year.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]